10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide

Rabbit Polyclonal Antibody

Catalog # AH10766

Specification

TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide - Product Information

Application	**IHC-P, IF, FC**
Primary Accession	P35625
Other Accession	7078, 644633, 714168
Reactivity	**Human, Mouse, Rat, Bovine, Horse, Dog**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**Rabbit / IgG**
Calculated MW	**30kDa KDa**

TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide - Additional Information

Gene ID 7078

Other Names
Metalloproteinase inhibitor 3, Protein MIG-5, Tissue inhibitor of metalloproteinases 3, TIMP-3, TIMP3

Application Note
IHC-P~~N/A<br \>IF~~1:50~200<br \>FC~~1:10~50

Format
200ug/ml of Ab purified from rabbit anti-serum by Protein A. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA at 1.0mg/ml.

Storage
Store at 2 to 8°C.Antibody is stable for 24 months.

Precautions
TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide - Protein Information

Name TIMP3

Function
Mediates a variety of processes including matrix regulation and turnover, inflammation, and angiogenesis, through reversible inhibition of zinc protease superfamily enzymes, primarily matrix

metalloproteinases (MMPs). Regulates extracellular matrix (ECM) remodeling through inhibition of matrix metalloproteinases (MMP) including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15. Additionally, modulates the processing of amyloid precursor protein (APP) and apolipoprotein E receptor ApoER2 by inhibiting two alpha- secretases ADAM10 and ADAM17 (PubMed:17913923). Functions as a tumor suppressor and a potent inhibitor of angiogenesis. Exerts its anti- angiogenic effect by directly interacting with vascular endothelial growth factor (VEGF) receptor-2/KDR, preventing its binding to the VEGFA ligand (PubMed:12652295). Selectively induces apoptosis in angiogenic endothelial cells through a caspase-independent cell death pathway (PubMed:25558000). Mechanistically, inhibits matrix-induced focal adhesion kinase PTK2 tyrosine phosphorylation and association with paxillin/PXN and disrupts the incorporation of ITGB3, PTK2 and PXN into focal adhesion contacts on the matrix (PubMed:25558000).

Cellular Location
Secreted, extracellular space, extracellular matrix

TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide - Images



Formalin-fixed, paraffin-embedded human Placenta stained with TIMP3 Rabbit Polyclonal Antibody.

TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide - Background

TIMP3 (tissue inhibitor of metalloproteinases 3), along with family members TIMP1, TIMP2, and

TIMP4, are inhibitors of the matrix metalloproteinases (MMPs), a group of peptidases involved in degradation of the extracellular matrix (ECM). An imbalance between MMPs and the associated TIMPs may play a significant role in the invasive phenotype of malignant tumors. TIMP s inhibit the proteolytic invasiveness of tumor cells and normal placental trophoblast cells. TIMP-3 may be involved in regulating trophoblastic invasion of the uterus as well as in regulating remodeling of the extracellular matrix during the folding of epithelia, and in the formation, branching and expansion of epithelial tubes.

TIMP-3 (Tissue Inhibitor of Metalloproteinase-3) Antibody - With BSA and Azide - References

Nagase, H. et al. (2006) Cardiovasc Res 69, 562-73. | Visse, R. and Nagase, H. (2003) Circ Res 92, 827-39. |